DataMeds AI Reports Settlement, Repurchases Shares; $19M Liability Off

What Happened
DataMeds AI, Inc. (MEDS) announced on Sept. 11, 2026 that it entered into a settlement agreement resolving related litigation with several former holders and intermediaries, including Brian Norton, Nomad Capital LLC and Strategix Global LLC. Under the agreement the Company paid $450,000 total—$350,000 attributed to repurchase and extinguishment of 364,099 shares of common stock and $100,000 as settlement consideration for the Membership Interest Purchase Agreement (MIPA) claims and other released claims. The parties agreed to dismiss the Florida and Delaware actions with prejudice and exchange mutual releases. As a result, the Company expects to extinguish approximately $19 million of liability currently on its consolidated balance sheet.

Key Details

• Settlement date: September 11, 2026; parties include Brian Norton (and others), Nomad Capital LLC and Strategix Global LLC.
• Cash paid: $450,000 total ($350,000 for repurchase/extinguishment of 364,099 shares; $100,000 for settlement of MIPA and released claims).
• Financial effect: Company anticipates eliminating about $19 million of liability from its consolidated balance sheet.
• Litigation outcome: Both the Florida and Delaware cases will be dismissed with prejudice and mutual releases executed.

Why It Matters
This settlement removes ongoing legal uncertainty and related disputes tied to the MIPA and certain shareholder claims, which can be a positive governance and risk-development for investors. The Company’s cash outlay is relatively small ($450k) compared with the substantial (~$19M) liability expected to be extinguished, which could materially improve reported liabilities on future financial statements. Investors should review the 8‑K and upcoming filings for how the repurchase and liability extinguishment are recorded in the Company’s books and any impact on shares outstanding.